Enterprise Solutions Webinars

  1. Avid Bioservices Capabilities Update July 2026: Large Molecule 8/7/2026

    Discover how integrated development and manufacturing can reduce risk, speed timelines, and support seamless progression from early development to commercial production.

  2. Built For Growth: Engineering Flexible And Scalable Bioprocessing Strategies 8/6/2026

    Standardizing bioprocess platforms and automation logic simplifies cross-site tech transfer and mitigates workforce constraints during program scale-up.

  3. Samsung Biologics Capabilities Update July 2026: Large Molecule 8/6/2026

    We offer end-to-end CDMO services across drug substance, drug product, ADC, mRNA, and organoid modalities, with 845,000L capacity and a 99% batch success rate. Evaluate your multi-plant sourcing framework now.

  4. Thermo Fisher Scientific Capabilities Update July 2026: Fill/Finish 8/6/2026

    When working with high-value biologics, ADCs, and personalized medicines, material utilization decisions made before GMP manufacturing can make or break your program yield. Learn how early choices matter.

  5. What Will It Actually Take To Build A Resilient Global Vaccine Supply Chain? 8/3/2026

    U.S. funding cuts could leave 75 million children without routine vaccines. Five supply chain leaders explain what resilience actually requires and what's at stake if the sector fails to act.

  6. How Sanofi Navigates Regulatory CMC Across Global Markets 8/3/2026

    Sanofi's Manda Pasarkar shares 20+ years of regulatory CMC expertise, covering FDA, EMA, and PMDA differences, CDMO partnerships, ICH guidelines, and AI's emerging role in global drug approvals.

  7. Tariffs, FDA Chaos, And BioSecure: How CDMOs Should Operate 8/3/2026

    Tariffs, FDA workforce cuts, and a stalled BioSecure Act are reshaping CDMO strategy. Get the full policy breakdown to stress-test your supply chain planning now.

  8. 6 CMC Strategies Are Transforming Biologics Drug Development 8/3/2026

    Sid Jain's two decades across Novartis, Regeneron, and Sanofi reveal six CMC strategies redefining how biologics reach the clinic, from CDMO selection to digital transformation pitfalls.

  9. Escape The Scale-Up Trap 8/3/2026

    Parallel single-use manufacturing eliminates vessel-transition risks, cutting lead times while preserving identical cell culture conditions from clinical trials to commercial launch.

  10. Step Inside Our Sterile Injectable Campus 7/30/2026

    Advanced automated filling lines and integrated development services streamline production, ensuring process integrity and faster timelines from early formulation to commercial supply.